PAR · ABVX.PA
Abivax S.A.
€81.10+€0.35 (+0.43%)
Abivax S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.65% below the high.
Loading market information…
PAR · ALVIO.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Valerio Therapeutics S.A.’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Valerio Therapeutics S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€81.10+€0.35 (+0.43%)
Abivax S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.65% below the high.
€30.32-€0.04 (-0.13%)
Nanobiotix S.A.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
€0.72-€0.01 (-1.63%)
Transgene S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.8% below the high.
€1.29+€0.01 (+0.63%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.81% below the high.
€1.10-€0.03 (-2.3%)
Cellectis S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.8% below the high.
€2.11-€0.08 (-3.84%)
OSE Immunotherapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.48% below the high.
€1.07+€0.03 (+2.69%)
MaaT Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 87.59% below the high.
€0.14+€0.02 (+16.5%)
TME Pharma N.V.’s quoted price sits in the upper half of its reported 52-week range, 19.93% below the high.
